New approaches to optimize treatment responses in chronic hepatitis B

Antiviral Therapy

Volumn 15, Issue SUPPL. 3, 2010, Pages 61-68

  Brunetto, Maurizia R ^a   Lok, Anna S ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LONG TERM CARE; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; PATIENT COMPLIANCE; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS TITRATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MEDICATION ADHERENCE;

EID: 77957330451     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1625     Document Type: Review

References (41)

1. European Association for The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
2. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49 Suppl 5:S103-S111.
3. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27:1736-1742.
4. Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36:1516-1522.
5. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
6. Lau GK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alfa-2a (40KD) [PEGASYS] one year post treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2006; 44 Suppl 2:S23-S24.
7. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459-467.
8. Brunetto MR, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003; 39 Suppl 1:S164-S167.
9. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
10. Marcellin P, Piratvisuth T, Brunetto M, et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post treatment follow up. J Hepatol 2009; 50:S336.
11. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323.
12. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
13. Lobello S, Lorenzoni U, Vian A, Floreani A, Brunetto MR, Chiaramonte M. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patients selection and treatment monitoring. J Viral Hepat 1998; 5:61-66.
14. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263-270.
15. Manesis EK, Hadziyannis SJ. Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101-109.
16. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and HBV-DNA as outcome predictors during therapy with peginterferon alfa 2a for HBeAg positive CHB. Hepatology 2008; 47:428-434.
17. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010; 40:269-277.
18. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
19. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
21. Chang TT, Lai C-L, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422-430.
22. Buti M, Hadziyannis S, Mathurin P, et al. Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis. J Hepatol 2009; 50 Suppl 1:S10.
23. Marcellin P, Liang J. A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antiviral Ther 2010; 15 Suppl 3:53-59.
24. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186-194.
25. Wu IC, Lai CL, Han SH, et al. Efficacy of entecavir in chronic hepatitis patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185-1189.
26. - hepatitis B patients treated with tenofovir showed no relationship between virological breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology 2009; 50:532A.
27. The Antiretroviral Pregnancy Registry. (Accessed 16 February 2010.) Available from www.apregistry.com
28. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
29. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51:73-80.
30. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11-20.
31. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
32. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
33. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
34. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
35. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
36. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
37. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
38. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analog treatment for chronic hepatitis B. Hepatology 2009; 50 Suppl 4:492A.
39. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
40. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48:728-735.
41. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HbeAg seroconversion is a major factor for sustained virologic response in HbeAg-positive chronic hepatitis B. Hepatology 2010; 51:415-421.